Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
The Korean Journal of Internal Medicine
;
: 43-45, 2006.
Artigo
em Inglês
| WPRIM
| ID: wpr-26004
ABSTRACT
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU). Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity. A 37-year-old female with gastric cancer underwent a curative operation, followed by adjuvant chemotherapy consisting of 5-FU and epirubicin. After the first cycle of chemotherapy, the patient manifested grade 2 mucositis and febrile neutropenia, and when her treatment was subsequently continued with doxifluridine she developed severe mucositis and febrile neutropenia. A PCR study revealed that her DPD mRNA level was lower than that in a control group. Thus, when considering the routine use of 5-FU for the treatment of cancer patients, an analysis of DPD activity or screening for DPD mutations is warranted in confined patients who experience unpredicted severe toxicity after initial 5-FU administration, even though DPD deficiency is a rare metabolic defect.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Gástricas
/
Adenocarcinoma
/
Fatores de Risco
/
Quimioterapia Adjuvante
/
Medição de Risco
/
Di-Hidrouracila Desidrogenase (NADP)
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Fluoruracila
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Estudo de etiologia
/
Fatores de risco
Limite:
Adulto
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS